The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Texas, USA-headquartered T-cell therapeutics company Triumvira Immunologics today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million. 17 March 2022
US biopharma Apellis Pharmaceuticals closed 13% higher at the end of Wednesday’s trading after announcing longer-term data from the Phase III DERBY and OAKS studies. 17 March 2022
To help combat the nationwide insulin affordability crisis, Civica Rx, a non-profit generic pharmaceutical company, has launched its Insulin Initiative with the JDRF. The initiative aims to drive affordability and accessibility for all Americans, regardless of insurance status. 17 March 2022
Further positive results from the OlympiA Phase III trial showed that AstraZeneca and Merck & Co’s Lynparza (olaparib) demonstrated a statistically-significant and clinically meaningful-improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy. 17 March 2022
Australian cancer patients will get improved access to local clinical trials through a new public-private partnership consortium, PrOSPECT, which today announced a funding agreement that is expected to enable a significant increase in local cancer clinical trial participation. 17 March 2022
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Japan’s Chugai Pharmaceutical resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). 17 March 2022
Shares of 2seventy bio were up almost 10% at $13.40 this morning, after the US immuno-oncology cell therapy company announced it has agreed to sell around13,934,427 shares of its common stock to a select group of institutional and accredited investors in a private placement. 16 March 2022
French pharma major Sanofi and US biotech company Seagen have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. 16 March 2022
Although Japanese drugmakers have been lagging behind the USA and Europe in the search for and launch of COVID-19 treatments and vaccines, Shionogi seems to be picking up momentum. 16 March 2022
UK-based biopharma Hemogenyx Pharmaceuticals has achieved proof of concept (POC) for its chimeric bait receptor (CBR) platform technology, news that sent its share price up by 9% in Wednesday morning’s trading. 16 March 2022
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. 16 March 2022
At the annual congress of the Muscular Dystrophy Association (MDA), Swiss pharma giant Roche has announced new data for its spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). 16 March 2022
Krystal Biotech, which is focussed on redosable gene therapies for rare diseases, saw its shares rise as much as 4.6% to $62.61 on Monday, as is said it has reached a binding term sheet with fellow US biotech firm PeriphaGen - and former lab partner - to resolve all claims it copied the latter’s gene therapy technology litigation filed by PeriphaGen on May 20, 2020. 16 March 2022
The Indian government has extended the application date till March-end for the PLI (production linked incentive) scheme for bulk drugs. The government said that after two rounds of inviting applications, a total 49 projects have been approved for 33 critical APIs with a committed investment of $483 million. 16 March 2022
Yesterday, the US Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions. 16 March 2022
Metagenomi, a California, USA-based genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced the appointment of Christine Foster, as chief business officer and Alan Cohen, as chief medical officer and senior vice president of Monogenic Diseases. 15 March 2022
Japanese drugmaker Eisai has backed out of its 50:50 profit sharing deal with US biotech company Biogen on the Alzheimer’s drug Aduhelm (aducanumab). 15 March 2022